Objective
The aim of this study was to evaluate the validity of selfâreported medication use for hypertension, diabetes, and dyslipidemia by comparison with health insurance claims among employees of largeâsized companies in Japan.
Methods
Participants were 61Â 676 participants of 13 largeâsized companies in Japan. Selfâreports on medication use were obtained through webâ or paperâbased questionnaires conducted at the annual health checkup in fiscal year 2016. Health insurance claims for medication were obtained from corporate health insurance associations from April 1, 2016, to March 31, 2017. Agreement rate, sensitivity, specificity, positive and negative predictive values (PPV and NPV), and kappa statistics of selfâreporting were examined for different reference periods (1â, 2â, and 3â months, and 1âyear). Subgroup analysis was conducted stratified by sex, age, body mass index, smoking, alcohol drinking, blood pressure, hemoglobin A1c, and lowâdensity lipoprotein cholesterol.
Results
Agreement, sensitivity, specificity, PPV, and NPV were 0.98, 0.90, 0.98, 0.87, and 0.99 for hypertension, 0.99, 0.89, 1.00, 0.89, and 1.00 for diabetes, and 0.98, 0.86, 0.99, 0.83, and 0.99 for dyslipidemia, respectively, between selfâreports and claims data for 3Â months. Kappa statistics were highest with the 3âmonth reference period of claims data for hypertension, diabetes, and dyslipidemia. No major concordance was observed between the subgroups.
Conclusion
This validation of selfâreported medication use for hypertension, diabetes, and dyslipidemia showed almost perfect reliability among employees of largeâsized companies in Japan.